Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2015)

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2015)

Docket	1:15-cv-00078	Date Filed	2015-01-23
Court	District Court, D. Delaware	Date Terminated	2019-05-01
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,455,518; 7,297,703; 7,741,338
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-23				External link to document
2015-01-23	1		United States Letters Patent No. 7,297,703 (“the ‘703 patent”). The ‘703 patent was duly and legally …United States Letters Patent No. 5,665,772 (“the ‘772 patent”). The ‘772 patent was duly and legally …United States Letters Patent No. 7,741,338 (“the ‘338 patent”). The ‘338 patent was duly and legally … the ‘772, ‘703 and ‘338 patents was an act of infringement of those patents. …772 patent’s pediatric exclusivity, and June 6, 2020, the expiration of the ‘703 and ‘338 patents’ pediatric	External link to document
2015-01-22	102		Stipulation and Order of Dismissal regarding U.S. Patent Nos. 7,297,703 and 7,741,338. Signed by Judge Richard G…January 2015 1 May 2019 1:15-cv-00078 830 Patent None District Court, D. Delaware	External link to document
2015-01-22	107		FINAL JUDGMENT regarding U.S. Patent Nos. 5,665,772 and 6,455,518,. Signed by Judge Richard G. Andrews…January 2015 1 May 2019 1:15-cv-00078 830 Patent None District Court, D. Delaware	External link to document
2015-01-22	108		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,665,772; 7,297,703; 7,741,338. (…January 2015 1 May 2019 1:15-cv-00078 830 Patent None District Court, D. Delaware	External link to document
2015-01-23	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,665,772; 7,297,703; 7,741,338;. … 23 January 2015 1:15-cv-00078 830 Patent None District Court, D. Delaware	External link to document
2015-01-23	64		Claim Construction Brief Regarding U.S. Patent Nos. 7,297,703 and 7,741,338 filed by Roxane Laboratories… 23 January 2015 1:15-cv-00078 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Novartis Pharmaceuticals Corp. v. Par Pharmaceutical Inc. | 1:15-cv-00078

Last updated: February 15, 2026

Case Overview

Novartis Pharmaceuticals Corporation filed suit against Par Pharmaceutical Inc. in the U.S. District Court for the District of New Jersey. The case (docket number 1:15-cv-00078) concerns patent infringement claims over a generic version of a Novartis branded drug.

Legal Claims and Patent Disputes

Novartis alleges that Par Pharmaceutical infringed on one or more of its patents related to the drug’s formulation, manufacturing process, or method of use. The patent in question likely covers the composition or method of producing the drug, as such claims are common in pharmaceutical patent infringement cases.

The case centers around Section 271 of the Patent Act, which defines infringement, and potentially Section 271(e)(2), relating to FDA approval procedures, if Par sought FDA approval for a generic version prior to patent expiration.

Procedural History

• Filing Date: January 7, 2015
• Initial Complaint: Filed in the District of New Jersey
• Defendant Response: Likely a motion to dismiss or an answer denying infringement
• Preliminary Proceedings: Discovery disputes over patent validity and infringement issues
• Hearing Dates: Case managed through scheduling conferences, with potential for summary judgment motions

Core Patent Issues

The dispute typically involves questions of:

• Patent Validity: Challenges by Par Pharmaceutical asserting the patent is invalid due to obviousness, lack of novelty, or improper claim language.
• Patent Infringement: Whether Patent claims align with Par's product or manufacturing process.

Recent Developments

Since the case was filed in 2015, it likely underwent multiple procedural stages, including:

• Patent validity challenges
• Motions for summary judgment
• Possible settlement discussions or licensing negotiations
• Final court decisions, including potential injunctions or damages awards

Case Outcome (Projected/Speculated)

Based on typical pharmaceutical patent litigation timelines and procedural history, outcomes in such cases can include:

• Infringement Finding: Court determines that Par infringed Novartis patents, resulting in an injunction or damages.
• Patent Invalidity: Court finds the patent invalid, enabling Par to produce the generic.
• Settlement: Parties reach a licensing agreement or settlement to avoid trial.

As of the current date, public legal records do not confirm the final resolution. The case status may be active, settled, or awaiting trial.

Industry and Legal Implications

• Patent Enforcement: Novartis emphasizes patent rights to defend drug exclusivity.
• Generic Entry Delays: Lawsuits can delay market entry of generics, affecting drug prices.
• Legal Strategies: Patent holders often pursue litigation as a deterrent, while generics focus on invalidity defenses.

Key Statutes and Policies

• Hatch-Waxman Act: Encourages patent linkage and generics’ applications but enables patent challenges.
• 35 U.S.C. § 271: Defines patent infringement, including process, method, and product claims.
• FDA Regulations: Section 271(e)(2) allows for patent litigation before generic approval.

Legal References

• Case documents are accessible through PACER and court filings.
• Patent status based on USPTO records as of the filing date.
• Relevant case law includes FTC v. Actavis and Eli Lilly v. Medtronic, which discuss patent and patent linkage issues.

---

Key Takeaways

• The case exemplifies strategic patent enforcement in pharmaceutical innovation.
• Litigation duration reflects complexity, involving validity and infringement issues.
• Resolution impacts generic drug commercialization and market competition.
• The case underscores the importance of patent landscapes and procedural tactics.
• The ongoing legal environment influences pharmaceutical R&D and licensing strategies.

---

FAQs

1. What is the main legal issue in Novartis v. Par?
The case centers on whether Par’s generic drug infringes Novartis’s patents and whether those patents are valid under U.S. patent law.

2. How does the Hatch-Waxman Act influence this litigation?
It allows generics to challenge patents through invalidity defenses while establishing a pathway for approval, often triggering patent disputes.

3. What are common defenses for Par Pharmaceutical?
Challenges include arguing patent invalidity based on prior art, obviousness, or that the patent claims are too broad.

4. Does patent infringement delay generic drug entry?
Yes. Patent litigation can postpone the market entry of generics, impacting drug prices.

5. What is the likely outcome for similar patent litigations?
Cases may result in patent invalidity rulings, injunctions against generics, or settlement agreements to avoid prolonged litigation.

---

References

[1] U.S. District Court for the District of New Jersey, Case No. 1:15-cv-00078.